Physician profile
Scott Lee
NPI 1063703890
$5,587.36
in general payments reported to CMS, 2019-2025
24 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.84 · 2021: $1,080 · 2022: $830 · 2023: $1,226 · 2024: $1,019 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,454 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,453.59 |
| Education | $205.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $915.05 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Abbvie INC. | $898.74 | 2020-2025 | |
| Madrigal Pharmaceuticals | $728.48 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $659.77 | 2021-2025 | Xifaxan, Trulance |
| Pfizer INC. | $449.47 | 2024-2025 | |
| Celgene Corporation | $202.75 | 2023-2024 | Zeposia |
| Genzyme Corporation | $202.35 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $187.13 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $154.91 | 2023 | Dupixent |
| Lilly USA, LLC | $148.76 | 2024 | Omvoh |
| Lucid Diagnostics INC. | $145.05 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.46 | 2022-2024 | Entyvio, Eohilia |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.04 | 2023 | Zeposia |
| Redhill Biopharma INC. | $96.78 | 2022-2024 | Talicia, Aemcolo, Movantik |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $84.44 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $81.56 | 2021-2024 | Suflave, Sutab |
| Celltrion USA INC. | $80.26 | 2024-2025 | Vegzelma, Zymfentra |
| Janssen Scientific Affairs, LLC | $78.30 | 2022 | |
| Intercept Pharmaceuticals, INC. | $19.55 | 2023 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $17.38 | 2025 | Iqirvo |
| Endogastric Solutions, INC | $17.30 | 2023 | Esophyx |
| Aimmune Therapeutics, INC. | $15.83 | 2025 | Vowst |
| Capsovision, INC. | $14.01 | 2023 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.